ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.55%
S&P ASX All Technology
3,016.30
1.48%
Brent Oil
82.765
0.00%
US Dollar vs AUD
1.514
0.00%
Bitcoin
63,808.47
-0.13%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alzamend Neuro Inc (ALZN)

  7. Alzamend Neuro Inc (ALZN) News

ALZN

Alzamend Neuro (ALZN)

Alzamend Neuro Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALZN
DateTimeSourceHeadlineSymbolCompany
08/03/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
03/02/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
06/01/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
16/12/202308:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
12/12/202300:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
21/11/202300:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
17/11/202308:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
17/11/202300:00Business WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNASDAQ:ALZNAlzamend Neuro Inc
14/11/202300:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
31/10/202307:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
30/10/202323:00Business WireAlzamend Neuro Announces Reverse Stock SplitNASDAQ:ALZNAlzamend Neuro Inc
23/10/202323:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
02/10/202323:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
30/09/202306:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
27/09/202308:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
23/09/202306:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
22/09/202322:00Business WireAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing RequirementNASDAQ:ALZNAlzamend Neuro Inc
14/09/202307:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
09/09/202307:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
09/09/202307:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
02/09/202306:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALZNAlzamend Neuro Inc
30/08/202322:00Business WireAlzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
25/08/202306:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
17/08/202306:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
11/08/202314:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALZNAlzamend Neuro Inc
11/08/202306:30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
08/08/202306:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
03/08/202306:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALZNAlzamend Neuro Inc
28/07/202306:56Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALZNAlzamend Neuro Inc
23/06/202306:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
 Showing the most relevant articles for your search:NASDAQ:ALZN

Your Recent History

NASDAQ
TSLA
Tesla
NYSE
JPM
JP Morgan Chase
ASX
TLS
Telstra
NASDAQ
AAPL
Apple
ASX
XMM
S&P ASX 300 Metals and M...
ASX
XFL
S&P ASX 50
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FTSE
UKX
FTSE 100
NASDAQ
GOOGL
Alphabet
ASX
MQG
Macquarie
PM
XAUUSD
Gold vs US Dollar
ASX
CSL
CSL
FX
GBPAUD
Sterling vs AUD
COIN
ETHUSD
Ethereum
NYSE
MCD
McDonalds
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved